Skip to content

Clinical observation trial of Anti-heart Failure Intelligent Formula King

Clinical observation trial of Anti-heart Failure Intelligent Formula King

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006012
Enrollment
Unknown
Registered
2022-05-15
Start date
2022-05-20
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure

Interventions

treatment group:Anti-heart Failure Intelligent Formula King+Western medicine basic treatment
control group:Placebo+Western medicine basic treatment

Sponsors

Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1) Age: 30-85 years old, male or female. 2) Based on meeting the diagnostic criteria of western medicine for heart failure, left ventricular ejection fraction = 50% or NT-proBNP level = 450 ng/L. 3) Patients with TCM syndrome of yang deficiency and water stasis, qi deficiency and blood stasis. 4) Requirements for medical records: chronic heart failure caused by coronary heart disease or myocardial infarction, with clinical findings of chronic heart failure for at least 3 months (the patient is in the early stage of heart failure, and the diagnosis is preferably 3-6 months). 5) Participants have New York Heart Association (NYHA) functional class of II to III and have received fixed-dose optimal treatment for at least 2 weeks. 6) Participants are volunteered to participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with other types of heart failure, including heart failure caused by valve disease, congenital heart disease, pericardial disease, arrhythmia or other noncardiogenic factors. 2) Possible coronary artery bypass surgery/cardiac resynchronization therapy within the next 4 weeks. 3) Uncorrected primary valvular disease, left ventricular outflow obstruction, myocarditis, aneurysm, uncontrolled severe arrhythmia, cardiogenic shock, unstable angina or acute myocardial infarction. 4) Serious primary liver, kidney or blood disease or serious mental health condition or other uncontrolled systemic diseases. 5) Serum creatinine level >194.5µM or serum potassium level >5.5mM. 6) Alanine aminotransferase or alkaline phosphatase levels > 1.5 times the upper normal limit. 7) Uncontrolled blood pressure, systolic blood pressure = 180mm Hg or diastolic blood pressure = 110mm Hg. 8) Lactating or pregnant women. 9) Known or suspected of being allergic to the study drug. 10) Received another study drug within 30 days before randomization. 11) Unwilling or unable to provide written consent.

Design outcomes

Primary

MeasureTime frame
NT-proBNP;six-minute walk test;

Secondary

MeasureTime frame
TCM syndrome score;electrocardiography;minnesota heart failure quality of life questionnaire;left ventricular ejection fraction;left ventricular end diastolic dimension;blood pressure;New York Heart Association (NYHA) functional classification;

Countries

Chian

Contacts

Public ContactJie Wang
wangjie0103@126.com010-88001817

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026